Candesartan Cilexetil Drug Market Report 2026

The candesartan cilexetil drug market size has grown strongly in recent years. It will grow from $1.65 billion in 2025 to $1.74 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing hypertension prevalence, clinical efficacy of ARBs, shift away from ACE inhibitors, expansion of cardiovascular treatment guidelines, rising aging population.

The candesartan cilexetil drug market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growth in chronic cardiovascular diseases, expanding generic drug penetration, increasing combination drug adoption, improved access in developing regions, rising preventive cardiovascular care. Major trends in the forecast period include rising use of angiotensin receptor blockers in hypertension, increasing prescription for heart failure management, growing demand for generic antihypertensive drugs, expansion of combination therapy formulations, improved patient compliance through once-daily dosing.

The rising prevalence of hypertension is expected to drive the growth of the candesartan cilexetil drug market in the coming years. Hypertension, or high blood pressure, is a condition in which the force of blood against the artery walls is consistently too high, typically defined as 130/80 mmHg or greater. This increase is largely attributed to unhealthy lifestyle factors, including poor diet, physical inactivity, and high stress levels. Candesartan cilexetil helps manage hypertension by blocking the action of angiotensin II, a hormone that constricts blood vessels, thereby relaxing the vessels and lowering blood pressure. For instance, in March 2023, the World Health Organization, a Switzerland-based intergovernmental organization, published that approximately 1.28 billion adults aged 30 to 79 globally have hypertension, with the majority (two-thirds) residing in low- and middle-income countries. It is estimated that 46% of adults with hypertension are unaware of their condition. Consequently, the growing burden of hypertension is driving demand in the candesartan cilexetil drug market.

The increasing prevalence of cardiovascular disorders is expected to drive the growth of the candesartan cilexetil drug market in the coming years. Cardiovascular disorders are conditions that affect the heart and blood vessels, impairing the heart’s ability to function effectively. This rise is largely linked to sedentary lifestyles, which can contribute to obesity, high blood pressure, and poor cardiovascular health by reducing the efficiency of the heart and circulation. Candesartan cilexetil helps manage these disorders by lowering blood pressure and reducing cardiac strain, thereby decreasing the risk of complications such as heart failure, stroke, and kidney damage. For example, in January 2025, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK - around 4 million men and 3.6 million women - lived with heart and circulatory diseases. These conditions account for nearly 27% of all deaths in the country, resulting in over 170,000 fatalities annually, or roughly 480 deaths per day. Consequently, the growing burden of cardiovascular disorders is fueling demand in the candesartan cilexetil drug market.

Leading companies in the candesartan cilexetil drug market are focusing on developing innovative formulations, including treatments for hypertension, combination therapies with other antihypertensive drugs, and extended-release versions, to improve patient adherence and enhance therapeutic outcomes. Hypertension treatment involves the use of medications, lifestyle modifications, and other interventions to lower and manage high blood pressure, reducing the risk of complications such as heart disease, stroke, and kidney damage. For example, in March 2025, Scienture Inc., a US-based pharmaceutical company, received USFDA approval for its New Drug Application (NDA) for SCN-102, launched as Arbli, a losartan potassium oral suspension (10 mg/mL). This angiotensin II receptor blocker (ARB) formulation provides an alternative for patients who have difficulty swallowing tablets, particularly in pediatric and geriatric populations. The launch highlights the growing interest in alternative dosage forms in the antihypertensive market and reflects a broader shift toward personalized, patient-friendly drug delivery systems.

Major companies operating in the candesartan cilexetil drug market are Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Viatris Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Torrent Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Oubari Pharmaceutical Co.

North America was the largest region in the candesartan cilexetil drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candesartan cilexetil drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the candesartan cilexetil drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the candesartan cilexetil drug market by increasing costs for imported APIs, intermediates, and excipients used in antihypertensive formulations. These impacts are most visible in generic tablet and capsule segments, particularly in North America and Europe where API sourcing is globally diversified. Asia-Pacific manufacturers have experienced pricing pressure and procurement delays due to trade dependencies. However, tariffs have encouraged domestic API manufacturing and localized formulation production, supporting long-term supply stability.

The candesartan cilexetil drug market research report is one of a series of new reports that provides candesartan cilexetil drug market statistics, including candesartan cilexetil drug industry global market size, regional shares, competitors with a candesartan cilexetil drug market share, detailed candesartan cilexetil drug market segments, market trends and opportunities, and any further data you may need to thrive in the candesartan cilexetil drug industry. This candesartan cilexetil drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Candesartan cilexetil is an angiotensin II receptor antagonist primarily used to treat high blood pressure and heart failure. It works by blocking the effects of angiotensin II, helping to relax blood vessels and lower blood pressure.

The main product types of candesartan cilexetil include tablets, capsules, and other forms. Tablets are solid dosage forms containing a mixture of active pharmaceutical ingredients and excipients, compressed into a convenient shape. It is indicated for conditions such as hypertension, heart failure, diabetic nephropathy, and left ventricular hypertrophy, with available strengths of 4 mg, 8 mg, 16 mg, and 32 mg. The drug is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and healthcare facilities, and is used across various patient groups, including adults, children, and adolescents.

The candesartan cilexetil drug market consists of sales of atacand, candesartan tablets, and oral tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.